Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
BörsenkürzelINDV
Name des UnternehmensIndivior PLC
IPO-datumDec 24, 2014
CEOCiaffoni (Joseph J)
Anzahl der mitarbeiter1030
WertpapierartOrdinary Share
GeschäftsjahresendeDec 24
Addresse234 Bath Road
StadtSLOUGH
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlSL1 4EE
Telefon448043791090
Websitehttps://www.indivior.com/en
BörsenkürzelINDV
IPO-datumDec 24, 2014
CEOCiaffoni (Joseph J)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten